 And it's pretty clear investors are missing the message, right, which is you're talking about this is the beginning of the next Regeneron, the next PureTech, the next Ligand. And you're seeing your front row seat. I would argue, though, and we don't talk about share price and such on this program, but I will tell you, your share price has done well this year. Oh, it has. And I'll tell you, but as far as people missing the message, you have to remember, though, they're coming off of that –